BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11488064)

  • 1. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
    Xu Y; McKenna RW; Molberg KH; Kroft SH
    Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.
    Fang JM; Finn WG; Hussong JW; Goolsby CL; Cubbon AR; Variakojis D
    Mod Pathol; 1999 Mar; 12(3):295-300. PubMed ID: 10102615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma.
    Yegappan S; Coupland R; Arber DA; Wang N; Miocinovic R; Tubbs RR; Hsi ED
    Mod Pathol; 2001 Nov; 14(11):1147-56. PubMed ID: 11706077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
    Uherova P; Ross CW; Schnitzer B; Singleton TP; Finn WG
    Am J Clin Pathol; 2001 Apr; 115(4):582-8. PubMed ID: 11293907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
    Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
    J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas.
    King BE; Chen C; Locker J; Kant J; Okuyama K; Falini B; Swerdlow SH
    Mod Pathol; 2000 Nov; 13(11):1219-31. PubMed ID: 11106080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
    Frost M; Newell J; Lones MA; Tripp SR; Cairo MS; Perkins SL
    Am J Clin Pathol; 2004 Mar; 121(3):384-92. PubMed ID: 15023043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
    Pedersen LM; Jürgensen GW; Johnsen HE
    Br J Haematol; 2005 Mar; 128(6):813-9. PubMed ID: 15755285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients.
    Liu YH; Xu FP; Zhuang HG; Lai KC; Xie D; Luo DL; Li L; Luo XL; Xu J; Zhang MH; Zhang F; Li HM
    Hum Pathol; 2008 Jun; 39(6):875-84. PubMed ID: 18440593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas.
    Xu Y; McKenna RW; Kroft SH
    Mod Pathol; 2002 Apr; 15(4):413-9. PubMed ID: 11950915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
    Gualco G; Weiss LM; Barber GN; Bacchi CE
    Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.
    Zinzani PL; Dirnhofer S; Sabattini E; Alinari L; Piccaluga PP; Stefoni V; Tani M; Musuraca G; Marchi E; Falini B; Baccarani M; Pileri SA
    Haematologica; 2005 Mar; 90(3):341-7. PubMed ID: 15749666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
    Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
    Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses.
    Biasoli I; Morais JC; Scheliga A; Milito CB; Romano S; Land M; Pulcheri W; Spector N
    Histopathology; 2005 Mar; 46(3):328-33. PubMed ID: 15720419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.
    Zhao XF; Young KH; Frank D; Goradia A; Glotzbecker MP; Pan W; Kersun LS; Leahey A; Dormans JP; Choi JK
    Am J Clin Pathol; 2007 Jan; 127(1):47-54. PubMed ID: 17145622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH.
    Chuang SS; Ye H; Du MQ; Lu CL; Dogan A; Hsieh PP; Huang WT; Jung YC
    Am J Clin Pathol; 2007 Oct; 128(4):558-64. PubMed ID: 17875505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement.
    Nakamura N; Nakamine H; Tamaru J; Nakamura S; Yoshino T; Ohshima K; Abe M
    Mod Pathol; 2002 Jul; 15(7):771-6. PubMed ID: 12118116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.